Susquehanna Fundamental Investments, LLC Arcus Biosciences, Inc. Transaction History

Susquehanna Fundamental Investments, LLC

  • $4.33 Trillion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 16, 2023
SELL
$15.96 - $23.15 $82,704 - $119,963
-5,182 Reduced 31.67%
11,180 $203,000
Q4 2022

Feb 14, 2023
BUY
$19.7 - $35.71 $322,331 - $584,287
16,362 New
16,362 $338,000
Q4 2020

Feb 16, 2021
SELL
$17.0 - $32.36 $688,500 - $1.31 Million
-40,500 Closed
0 $0
Q3 2020

Nov 16, 2020
BUY
$17.14 - $25.47 $437,070 - $649,485
25,500 Added 170.0%
40,500 $694,000
Q2 2020

Aug 14, 2020
BUY
$13.97 - $36.56 $209,550 - $548,400
15,000 New
15,000 $371,000

Others Institutions Holding RCUS

# of Institutions
200
Shares Held
51.5M
Call Options Held
236K
Put Options Held
141K
View Full List

About Arcus Biosciences, Inc.

RCUS Quotes by TradingView
  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.02B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Susquehanna Fundamental Investments, LLC Portfolio

Follow Susquehanna Fundamental Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email